Background: Trauma-focused cognitive behavioral therapy (Tf-CBT) and eye movement desensitization and reprocessing (EMDR) are two highly effective treatment options for posttraumatic stress disorder (PTSD). Yet, on an individual level, PTSD patients vary substantially in treatment response. The aim of the paper is to test the application of a treatment selection method based on a personalized advantage index (PAI).
INTRODUCTION
Within the context of evidence-based medicine, a series of clinical practice guidelines for posttraumatic stress disorder (PTSD) have been developed and published internationally (e.g., Foa, Keane, Friedman, & Cohen, 2008; National Institute for Health and Clinical Excellence, 2005) . In a review, Forbes et al. (2010) examined existing guidelines and concluded that trauma-focused cognitive behavioral therapy (Tf-CBT) is consistently recommended as first-line psychological treatment, whereas eye movement desensitization and reprocessing (EMDR) is not always endorsed as equivalent. Despite these differences, CBT as well as EMDR have been shown to be highly effective for the treatment of PTSD in several randomized controlled trials (RCTs) and systematic reviews (Benish, Imel, & Wampold, 2008; & Gray, 2008; Van Etten & Taylor, 1998; Van Minnen, Arntz, & Keijsers, 2002) . Furthermore, several studies show that between 41 and 58% remain clinically distressed after treatment (Resick et al., 2002; Tarrier et al., 1999) . In a review, Schottenbauer et al. (2008) report nonresponse rates as high as 50%. Despite research results that show equivalent outcomes on average for Tf-CBT and EMDR, individual patients might respond differently to each of the two treatments. It is possible that a treatment that is highly effective for one patient might be ineffective or even harmful for another patient. Based on this argument, Schnyder (2005) , for example, suggests a need to develop new treatments for PTSD. In contrast, Seidler and Wagner (2006) argue that future research should focus on understanding which patients are more likely to benefit from one treatment or the other.
In this sense, clinical research is gradually shifting to an increased focus on the individual patient. Tailoring treatments to the specific characteristics of a patient is an approach that has been described as precision medicine. This approach has a long tradition in medicine, exemplified by attempts to identify genetic and neuroimaging markers that predict differential treatment response to pharmacological treatments (see Hamburg & Collins, 2010) . In the context of psychotherapy research, different strategies have been applied to empirically define the most promising treatment for a particular patient (e.g., Cohen & DeRubeis, 2017; Cuijpers, 2014; DeRubeis et al., 2014; Kessler et al., 2017; Lutz, De Jong, & Rubel, 2014; Lutz et al., 2006; Ng & Weisz, 2016 ).
Thus far, in the context of psychotherapy research, some studies have focused on the task of developing prognostic and/or prescriptive models for differential treatment selection. A model is called prognostic if the variables included predict response in a single treatment, whereas prescriptive variables are often referred to as moderators that affect the direction or strength of the differences in outcome between two or more treatment conditions (Cohen & DeRubeis, 2017) . In this sense, DeRubeis et al. (2014) developed a prescriptive model, which they called personalized advantage index (PAI).
Implemented in the context of two highly effective treatments, the PAI predicted a clinically meaningful advantage for 60% of depressed patients if they had been assigned to their predicted optimal treatment. Huibers et al. (2015) applied the same approach to a sample where depressed patients were randomized to either cognitive therapy or interpersonal psychotherapy (N = 134). The PAI was able to predict a clinically meaningful advantage in one of the therapies for 63% of the sample. More recently, Delgadillo, Huey, Bennett, and McMillan (2017) used data from a large naturalistic cohort (N = 1,512) of patients to construct a prognostic index. They found that a subgroup of patients referred to as "complex cases" tended to attain significantly better outcomes if they were initially assigned to high-intensity psychotherapies, rather than low-intensity CBT. Similarly, Kessler et al. (2017) recommended using prognostic models to estimate predictions for each treatment type, ideally using large naturalistic clinical samples to identify reliable predictors that could be applied in future clinical trials.
In summary, the application of treatment selection based on prognostic and prescriptive models has mainly focused on samples of patients suffering from depression, where they were most often randomly assigned to different treatments. However, heterogeneity in treatment response is not limited to patients with major depression. As highlighted above, PTSD is heterogeneous in presentation and prognosis, and therefore this diagnosis is not in itself sufficient for making an optimal treatment decision. On this basis, the objective of the present study was to develop a treatment selection method using data from a naturalistic PTSD sample where patients were treated either with Tf-CBT or EMDR in order to identify the optimal treatment for each patient.
METHODS
This study was based on the analysis of anonymous clinical case records for N = 317 patients accessing treatment for PTSD in a primary care mental health service in the north of England. This service was part of the national Improving Access to Psychological Therapies (IAPT) programme in England, which offers evidence-based psychological interventions organized in a stepped care model (Clark, 2011) .
Patients with PTSD received either Tf-CBT (Ehlers, Clark, Hackmann, McManus, & Fennell, 2005) or EMDR (Shapiro, 2001) . Table 1 ).
Measures

Patient Health Questionnaire 9
The Patient Health Questionnaire 9 (PHQ-9) is a validated nineitem screening tool, which is routinely used in IAPT services to measure symptom improvement (Kroenke, Spitzer, & Williams, 2001 ). The questionnaire has been developed to measure depression. Patients rate each item on a 0-3 scale (0 = "not at all" to 3 = "nearly every day"), yielding a total score between 0 and 27. A difference of six points on the PHQ-9 was taken as a reliable change index (Richards & Borglin, 2011) . Classification of PHQ-9 scores following Kroenke et al. (2001) : mild depression ≥5, moderate depression ≥10, moderately severe depression ≥15, and severe depression ≥20.
The mean level of baseline depression severity in this sample was PHQ-9 = 16.32. We did not have a PTSD-specific outcome measure available in this sample, however the PHQ-9 has been shown to be strongly associated (r = 0.59) with PTSD symptoms (Gerrity, Corson, & Dobscha, 2007) , and therefore using it as a primary outcome could be justified. The PHQ-9 has also been extensively validated 
Generalized Anxiety Disorder 7
The Generalized Anxiety Disorder 7 (GAD-7) is a seven-item measure developed to screen for anxiety disorders (Spitzer, Kroenke, Williams, & Löwe, 2006) . Each item is also rated on a 0-3 scale, yielding a total anxiety severity score between 0 and 21. In the following, the instrument served as potential predictor variable.
Work and Social Adjustment Scale
Functional impairment was assessed using the Work and Social Adjustment Scale (WSAS) (Mundt, Mark, Shear, & Griest, 2002) . The WSAS measures the extent to which mental health problems impair daily functioning across five domains (work, home chores, social leisure, private leisure, and relationships). The internal consistency of the WSAS has been found to range from = .70 to = .94 with a test-retest reliability of r = .73 (Mundt et al., 2002) . Initial WSAS scores were included in the process of identifying treatment-specific predictors.
Data analysis strategy 2.2.1 Missing data
To address missing data, including missing outcome assessments, we implemented a nonparametric missing value imputation procedure using random forests with the R package missForest (Stekhoven, 2013; Stekhoven & Bühlmann, 2012) . Imputation via missForest has been shown to yield a lower imputation error than other common imputation approaches (Waljee et al., 2013) . Table 1 gives an overview of missing values in the analysis sample. A good performance of missForest for continuous variables is assessed with the normalized root mean squared error (NRMSE) and for categorical variables using a proportion of falsely classified entries (PFC) close to zero (Stekhoven & Bühlmann, 2012) . Imputation was successful with a NRMSE of 0.30 and a PFC of 0.12. All further depictions and analyses are based on the imputed dataset.
Propensity score matching
As the present data stem from a naturalistic treatment context, we had to adjust for confounding by indication. Therefore, we implemented propensity score matching (PSM; Lutz, Schiefele, Wucherpfennig, Rubel, & Stulz, 2016; Rosenbaum & Rubin, 1983) . PSM can be used to match or to equate groups based on comparable baseline characteristics (West et al., 2014) . We performed PSM in R based on the
MatchIT package (Ho, Imai, King, & Stuart, 2011) using optimal matching. Optimal matching finds the matched samples with the smallest average absolute distance across all the matched pairs based on all available baseline characteristics. The process was iterated until all optimal matches between the EMDR sample and the Tf-CBT sample were found. For this study, we implemented the standardized mean difference (SMD) technique, a widely used method to check covariate balance between samples (e.g., Guo & Fraser, 2014) . The SMD method is similar to Cohen's d and allows the comparison of differences in matched and unmatched conditions for each covariate (with the SD of the unmatched condition being used as the denominator) (Cohen, 1992) . A SMD < .25 indicates acceptable match between samples on the respective covariates (Rubin, 2001) . For further analyses, all predictors were centered within the respective treatment condition:
continuous variables were grand mean centered, whereas dichotomous variables were dummy coded with values set to -0.5 and 0.5 (Kraemer & Blasey, 2004) .
Selection of variables via a genetic algorithm
Traditional methods for model selection are based on null hypothesis testing (e.g., Anderson, 2007; Anderson & Burnham, 2002) . This often includes a stepwise procedure where the researcher fits the full model and looks for terms that are not statistically significant, that is, whose removal does not significantly reduce the fit of the model. The procedure can be repeated until all effects in the formula are found significant. This approach is often called "backward elimination." A similar strategy is to start from the simplest model and to sequentially add the most significant effects (a "forward selection" approach). Hence, for each step, a significance test is needed to determine whether the removal or addition of a given term is useful. As the number of tests is typically high, this poses the problem of choosing a relevant significance level (Harrell, 2001 ).
We used a genetic algorithm (GA) for model selection, which overcomes the above-described problems of traditional methods and is considered to be robust and efficient (Calcagno & Mazancourt, 2010) .
The basic idea of the algorithm is that there is not one perfect model, but a set of candidate models that are satisfactory, which results in a set of variables that are important for further analyses. The importance of a predictor variable is calculated by summing up the weights for the models in which the variable appears. We used an 80% importance threshold to differentiate between important and not so important variables (Calcagno & Mazancourt, 2010) .
In this paper, we implemented GA in R based on glmulti, a package for automated model selection (Calcagno, 2013) . The package produces model formulas, which are passed through a fitting function. In our case, this fitting function is a linear regression model with treatment outcome (PHQ-9 final score) as dependent variable. We included initial symptom measures (PHQ-9, WSAS, GAD-7) as well as other available variables (comorbid long-term medical condition, disability, antidepressant medication, gender, age, employment status) as candidate predictors in the model selection process. Medication and employment status were included in the analysis as binary variables. The medication variable included cases that were "prescribed antidepressant medication" (52.17%) and those who were "prescribed but not taking antidepressant medication" (1.34%) into a single category (coded 0.5), with "no prescribed medication" (46.49%)
as the reference category (coded −0.5). Employment status was collapsed merging "employed" (50%) and "student" (3.47%) into a single category (coded 0.5) versus "unemployed" ("unemployed" (2.43%), "long-term sick" (11.46%), and "other" (32.64%), which was the reference category (coded −0.5) (see Table 1 for a more detailed description concerning treatment groups). As interactions of variables with treatment conditions require large sample sizes (Calcagno & Mazancourt, 2010) , we computed separate models for each treatment (Kessler et al., 2017) .
Personalized advantage index
We used a leave-one-out approach (DeRubeis et al., 2014; Efron & Gong, 1983) In the next step, the aim was to test the within-sample utility of the model for enhancing the treatment outcome through treatment assignment. First, we examined the true error as the average of the absolute difference between the observed scores and factual predictions. Second, we examined the observed change scores of the patients.
For that we compared the predictions from the two regression models for every patient and we refer to the treatment condition predicted to have a greater benefit as the optimal treatment, whereas the other is referred to as a suboptimal treatment. We then classified patients accordingly as having received the optimal or suboptimal treatment and compared the rates of clinically significant improvement achieved in both groups between pre-and postassessments (difference of six points on the PHQ-9; Richards & Borglin, 2011) . To aid interpretation from a clinical perspective, we calculated the number-needed-to-treat (NNT) using the formulae provided by Kraemer and Kupfer (2006) . 
RESULTS
Comparison of Tf-CBT and EMDR
Comparing the effect sizes (Cohen's d) between treatment conditions, there were no significant differences between Tf-CBT (PHQ-9: Table 2 ).
Independent-samples t tests and 2 tests were calculated to further compare baseline variables (see Table 1 ) between the two treatment conditions. In summary, the two naturalistic samples differed systematically in a number of the investigated baseline variables, as was to Tf-CBT, trauma-focused cognitive behavioral therapy; EMDR, eyemovement desensitization and reprocessing; PHQ-9, patient health questionnaire 9; GAD-7, generalized anxiety disorder 7; WSAS, work and social adjustment scale. a Effect size d was computed using the pooled standard deviation of pre-and posttreatment scores.
be expected in observational data. Consequently, PSM was necessary before selecting variables for model building.
Propensity score matching
The matching process via optimal matching (Ho et al., 2011) with all baseline variables resulted in a subsample of 150 patients of the Tf-CBT sample while all EMDR (N = 75) cases were included (see Table 1 ). After applying PSM, all baseline variables were sufficiently well balanced, as none of the SMD scores exceeded .25. The sample selection process is presented as a flowchart in Figure 1 . For correlations of baseline variables (see Table A1 ).
Separate variable selection for Tf-CBT and EMDR
Relevant variables for Tf-CBT
The GA selected four variables for Tf-CBT (see Tables 3 and 4 ).
Higher functional impairment (WSAS) at the beginning of therapy significantly predicted higher PHQ-9 end scores (B = 0.24, t(147) = 4.30, P < 0.001), whereas female patients showed better therapy outcomes (B = −2.09, t(147) = −1.93, P = .06). Furthermore, being employed and being older led to significantly better therapy outcomes (B = −4.99, t(147) = −4.21, P = .001; B = −0.10, t(147) = −2.51, P = .01).
F I G U R E 1
Flowchart of sample preparation and selection. IAPT, improving access to psychological therapies; PTSD, posttraumatic stress disorder; crossover cases, patients treated by therapists that offered both treatments; Tf-CBT, trauma-focused cognitive behavioral therapy; EMDR, eye movement desensitization and reprocessing; PSM, propensity score matching Tf-CBT, trauma-focused cognitive behavioral therapy; EMDR, eyemovement desensitization and reprocessing; PHQ-9, patient health questionnaire; medication, "prescribed antidepressant medication" coded as 0.5 with "no prescribed antidepressant medication" as reference category; employed, "employed" coded as 0.5 with "unemployed" as reference category; WSAS, work and social adjustment scale; gender, female coded as 0.5. *** P < .001, ** P < .01, * P < .05.
TA B L E 3 Important values for predictor variables for Tf-CBT and EMDR
Importance Importance
Tf-CBT (N = 150) EMDR (N = 75)
Relevant variables for EMDR
For EMDR, the variable selection process identified two variables (see Table 3 ). First, higher PHQ-9 scores at the beginning of treatment significantly predicted higher end scores in the same instrument (B = 0.44, t(72) = 2.77, P < 0.001). Furthermore, patients who were prescribed antidepressants tended to have poorer treatment outcomes compared to patients who were not prescribed medications (B = 4.40, t(72) = 3.77, P < 0.01; see Table 4 ).
F I G U R E 2
Distribution of predicted PHQ-9 postscores in the optimal and suboptimal treatment. Optimal, treatment condition with a predicted benefit for the individual patient; suboptimal, treatment condition that is predicted as being less effective for the individual patient
Personalized advantage index
The prediction of an individual's final PHQ-9 score was developed separately for each treatment condition based on treatment-specific pre- To further test the utility of our approach, we compared the rates of reliable improvement between patients who had their optimal or their suboptimal treatment based on the treatment-specific predictors. Table 5 shows that 63% (n = 78) of the patients who received their optimal treatment (n = 124) had a reliable improvement after TA B L E 5 Testing the utility of the PAI approach with regard to observed scores and reliable change Optimal Suboptimal PAI, personalized advantage index; Reliable change index ≥ 6 for the PHQ-9 (Richards & Borglin, 2011) ; optimal, treatment condition with a predicted benefit for the individual patient; suboptimal, treatment condition that is predicted as being less effective for the individual patient.
F I G U R E 3
Distribution of PAI scores. PAI, personalized advantage index (magnitude of the predicted difference between optimal and suboptimal treatment); ½ SD, 0.96; 1 SD, 1.92; 2 SD, 3.85 treatment, while in the group of patients who received their suboptimal treatment, this was only true for 33.66% (n = 34). In total, the model prediction was true for 64.44% (n = 145) of the total sample (n = 225). The presented frequencies in Table 5 were significantly different, 2 (1, n = 225) = 19.54, P < .001.
Based on the predictions, the PAI for each individual patient was calculated by subtracting the predicted outcomes for the modeldetermined optimal treatment from the suboptimal treatment. The average PAI was 2.49 (SD = 1.92; 0.01-9.34), representing an expected average of 2.49 point difference in PHQ-9 post-treatment scores between the predicted optimal treatment (predicted M = 7.97, SD = 3.47, 0.62-14.56) versus the suboptimal (predicted M = 10.47, SD = 3.68, 2.36-18.07) treatment. The predicted benefit of treatment selection is displayed in Figure 3 based on the frequencies of PAI scores. Note that the PAI can be as low as zero, which occurs when the same outcome is predicted for both treatments. For 32 patients (14.22%), the PAI was close to zero (PAI ≤ 0.5) meaning that for those patients there was no predicted difference between the two treatment conditions. Helping to classify the importance of the difference between predicted optimal and suboptimal treatment, the PAI was further inspected regarding its SD; see Figure 3 . Hence, a PAI of 0.96 corresponds to half a SD. In our sample, 171 patients (76%) had a PAI of this size or larger. Furthermore, 55.56% (n = 125) of the patients had a PAI that corresponds to one SD. From those, 63 patients (49.6%) did not receive their model-predicted optimal treatment and could have benefited from an algorithm-based treatment assignment. A PAI equal or higher than two SDs was true for 22.67% (n = 51) of the patients of the sample.
DISCUSSION
This is the first study using the PAI approach in a naturalistic PTSD sample treated by either Tf-CBT or EMDR. We explored how patients' pretreatment characteristics may guide optimal treatment assignment to enhance therapy outcome for PTSD patients in the context of otherwise highly effective treatments.
Main findings
In the matched naturalistic treatment conditions, we identified treatment-specific outcome predictors. For Tf-CBT, functional impairment, age, gender, and employment status were significant predictors.
For EMDR, initial impairment and prescribed antidepressant medications were significant variables for outcome prediction.
As expected, outcomes for patients who received their modeldetermined optimal treatment were better than those of patients who received their suboptimal treatment. Patients in their model-predicted optimal treatment finished treatment with PHQ-9 scores in the range of mild depression, whereas observed scores for those who received their suboptimal treatment were still in the range of moderate depression. Although the difference in absolute terms between those two groups could be classified as small (3.03 points difference in PHQ-9 units), it corresponds to a NNT close to four. Bearing in mind that in the present study two highly effective treatments for PTSD were compared with each other, a NNT of four is an impressive effect size difference. In comparison, a meta-analysis that focused on the relative efficacy of psychotherapies for PTSD reported an effect size of 0.16 that translates into NNT = 12 (Benish et al., 2008) . Concerning the prediction models, 56% (n = 125) of the sample had a PAI equal or higher than one SD. From those, 50% (n = 63) did not receive their model-predicted optimal treatment and could have benefited from an algorithm-based treatment assignment.
Our results are consistent with existing literature in which the PAI predicted a meaningful advantage for approximately 60% of cases receiving their optimal treatment (DeRubeis et al., 2014; Huibers et al., 2015) . Despite these similarities, there are important differences concerning diagnoses, outcome measures, and definitions of clinically important change. Nevertheless, as in previous studies, we found that the PAI approach is promising enough in retrospective samples to justify its application prospectively in applied research studies.
It is still unclear if it is better to build treatment selection models by searching for moderators that are interactions of predictors with treatment in the whole sample (prescriptive models) or by developing separate prognostic models within each treatment condition. Until now, most of the PAI studies used a prescriptive approach (e.g., DeRubeis et al., 2014; Huibers et al., 2015) . Others suggested using prognostic models in large observational treatment studies to answer questions concerning personalized predictions (e.g., Delgadillo et al., 2017; Kessler et al., 2017) . Up to this point, there is no empirical evidence to guide us on the relative strengths, weaknesses, or differences between these modeling strategies. We decided to use a prognostic approach as finding interactions in small samples has low statistical power. Nevertheless, future research needs to address this empirical question.
Strengths and limitations
The current study is the first to apply the PAI approach in a naturalistic PTSD sample. So far, research investigated the PAI approach focusing solely on depression RCT samples. RCT samples are highly selective as only those patients can be included who agree to be treated with each of the treatments investigated. The present study used a patient preference design where patients can choose between two available treatments within the context of routine care. As a consequence, in a RCT sample model selection is compared to randomization, which is far from being an approach used in routine care. In contrast to that, due to the present study design, model prediction is compared to patient preference that has more meaning for clinical practice. That is, our results
show that with a machine learning based approach for treatment selection, better outcomes can be achieved than with a selection based on patient preferences. Of course, this assumes that patients who have a preference for a certain treatment can be convinced by the data to select a different treatment than their preferred one if this promises better outcomes for them. However, even if patients agree to undergo a treatment that is not their first choice, it is unclear whether this preference per se might influence treatment outcomes. Future applications of the PAI in RCTs and naturalistic contexts explicitly need to take patient preferences into account in order to get a better understanding of the role of this potentially important variable.
Apart from this, the use of retrospective data to determine the potential utility of the PAI still raises some questions about the viability, acceptability, and potential effects of using this strategy to prospectively assign patients to treatments. Nonetheless, a GA as well as a leave-one-out approach was implemented to enhance the probability that the identified predictor variables will be replicated in other samples. Furthermore, we have demonstrated and replicated the usefulness of the PAI approach, which justifies the effort to conduct prospective studies. To our knowledge, there is only one project that is applying prospective personalized treatment recommendations in an outpatient clinic (Lutz, Zimmermann, Müller, Deisenhofer, & Rubel, 2017) . Instead of the PAI, personalized predictions are based on a nearest neighbor approach. In our view, this is the first step to bring personalized treatments finally within reach (Cuijpers & Christensen, 2017) .
A further limitation concerns the relatively small sample size in which these models were evaluated. There is a potential risk of overconfidence due to the fact that variable selection was performed on the full sample. Unfortunately, due to the sample size we could not test the validation of our analyses in an external validation sample. There is a clear need for replications in bigger samples that allow external validation.
Another limitation refers to the main outcome measure PHQ-9, which is an instrument to assess depressive symptoms, but which in English IAPT services is one of the few mandatory instruments in routine data collections. Consequently, our results may not generalize to PTSD symptoms assessed with disorder-specific measures. Nevertheless, we still found meaningful differences between optimal and suboptimal treatments and they therefore encourage future investigations using PTSD-specific instruments (Brewin, 2005) . One possible explanation of our finding is that depression is one of the most common comorbid diagnoses in PTSD (Bradley et al., 2005) .
PSM has its advantages and limits, and this study is no exception (Shadish, 2013) . Although the method is able to account for observed potential confounders, there is still the possibility that unobserved variables might have had an influence on treatments, treatment selection, or therapy outcome. Nevertheless, we think that complete elimination of bias is unrealistic and the advantage of implementing the PAI in routine care data outweighs the potential shortcomings of the matching method.
CONCLUSIONS
Acknowledging the above limitations, this article adds to the growing body of research on personalized treatments in psychotherapy research. Results suggest that it is possible to enhance individual treatment outcomes in assigning PTSD patients to their optimal treatment.
This kind of study promotes the development of meaningful decision trees, which will result in supported clinical decision making (see Lutz, de Jong, & Rubel, 2014) . In the future, PAIs could be integrated in the diagnostic process at the beginning of psychotherapy to find the optimal treatment for a patient in advance. Matching patients to their model-determined optimal treatment could potentially further enhance treatment outcomes.
